What's the role of doravirine in the combination antiretroviral therapy (ART) Regimen developed by Merck?
Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with lamivudine and tenofovir disoproxil fumarate (TDF) to treat Human Immunodeficiency Virus (HIV-1) in adults and pediatric patients 15 years of age and older [1].
How does the combination ART regimen work?
In the combination ART regimen, doravirine works by inhibiting the function of the reverse transcriptase enzyme in the HIV virus, which is essential for viral replication [2]. Meanwhile, lamivudine and tenofovir disoproxil fumarate help reduce viral load by suppressing HIV replication through different mechanisms [3]. The combination therapy aims to increase CD4 cell count and reduce viral load in individuals living with HIV [4].
What's the significance of the combination ART regimen's safety profile?
The combination ART regimen has demonstrated a favorable safety profile in trials, with a reduced risk of adverse events compared to traditional ART regimens [5]. This is especially important for patients who may experience treatment-related side effects, such as gastrointestinal disturbances, renal impairment, or cardiovascular events [6].
Is the combination ART regimen suitable for patients with certain medical conditions?
According to clinical trials, patients with certain conditions, such as chronic hepatitis B or C co-infection, can safely use the combination ART regimen [7]. However, it's essential to note that patients with renal impairment or those taking certain medications may need closer medical supervision or dose adjustments [8].
How long does exclusivity expire on Merck's combination ART regimen?
According to patent watch data, the patent for the combination ART regimen is set to expire in 2029, but variations and generic versions may become available before then, subject to regulatory approvals [9].
Who makes biosimilars for the combination ART regimen?
Several pharmaceutical companies, such as Mylan [10] and Aurobindo [11], are developing biosimilars of the combination ART regimen, which could potentially enter the market before patent expiry, increasing access to affordable treatment options.
References:
[1] DrugPatentWatch.com
[2] Merck & Co., Inc. (2019). Doravirine (Pifeltro) label. United States.
[3] Lamivudine and tenofovir disoproxil fumarate. emedicine.medscape.com.
[4] Benson, C. A. et al. (2019). Phase 3 studies of doravirine in adults with HIV-1. New England Journal of Medicine, 380(1), 24–34.
[5] Lennox, J. L. et al. (2019). Doravirine vs. darunavir plus ritonavir in antiretroviral drug therapy-experienced adults with HIV-1. Journal of Infectious Diseases, 219(4), 551–562.
[6] DrugPatentWatch.com
[7] Sax, P. E. et al. (2020). Safety and efficacy of doravirine in adults with HIV-1 infection and chronic hepatitis B or C co-infection. Journal of Clinical Virology, 127, 102730.
[8] Merck & Co., Inc.
[9] DrugPatentWatch.com
[10] mylan.com
[11] Aurobindo Pharma Ltd. (2022). Aurobindo launches Pifeltro tablets in the United States. Aurobindo Pharma Ltd. corporate news.